Navigation Links
Alfacell Corporation to Present at UBS Global Life Sciences Conference
Date:9/19/2007

SOMERSET, N.J., Sept. 19 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL) today announced that Lawrence A. Kenyon, executive vice president, chief financial officer and corporate secretary, will present an overview of the company's product development programs at 8:30 a.m. EDT on Sept. 26, 2007, at the UBS Global Life Sciences Conference at the Grand Hyatt Hotel in New York City.

The live Webcast of the presentation will be available on Alfacell's Web site at http://www.alfacell.com. A replay of the Webcast will be available online for 30 days.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE(R), is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of ONCONASE in non-small cell lung cancer (NSCLC) and other solid tumors. For more information, visit http://www.alfacell.com.

Safe Harbor

This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that wo
'/>"/>

SOURCE Alfacell Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. In Vitro and In Vivo Data Show Alfacells Onocanse is Active Against Naive and Chemoresistant Neuroblastoma Cells
3. Preclinical Data Show Alfacells Onconase Inhibits Tumor Growth of Non-Small Cell Lung Cancer, Breast Cancer Cells
4. Researchers Identify Intracellular Pathway of Alfacells Onconase
5. In vivo Study Results Demonstrating Potential of Alfacells Onconase for Treatment of Non-Small Cell Lung Cancer Published in Anticancer Research
6. Studies Show Mild Hyperthermia Enhances Antitumor Effects of Alfacells Onconase
7. Alfacells Onconase Highlighted in Latest Edition of Handbook of Therapeutic Antibodies
8. Millipore Corporation Announces New ReNcell Data from Collaboration with ReNeuron
9. NanoBio Corporation Announces Positive Phase 1 Clinical Results for Topical Treatment for Onychomycosis
10. Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease
11. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2008)...RNewswire/ -- Axentis Pharma AG has,initiated a cl...lerability,of a new therapeutic formulation for th...c fibrosis patients. The new formulation allows an...ectly to the site of,infection. The forthcoming tr... doses of the new drug. Initial results are expect...
(Date:9/4/2008)...cation for Targeted Therapies That En...TON BEACH, Calif., and AMSTERDAM, Netherlands, Sep...lecular cancer diagnostics,today announced the la...,allows physicians to quantitatively determine the...ER), progesterone receptor (PR) and Human Epiderma...
(Date:9/3/2008)...g Children Studied. Wrong,Conclusions Reached., N...ters for Disease,Control and Prevention (CDC) stud...he MMR vaccine and autism. The National Autism Ass...pel the growing public concern over a,vaccine-auti...ing design,and methodology., For years, parents h...
(Date:9/3/2008)...chronically infected Hepatitis C,patients strongly... in 2008, - Study is the first to show a statist...effect of therapeutic Hepatitis C vaccination, -...a second generation, vaccine formulated with Inte... activation, VIENNA, Austr...
Breaking Medicine Technology:Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 2Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 3Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 4Agendia Launches TargetPrint(R) for Breast Cancer Patients 2CDC Misses Target With Flawed MMR/Autism Study 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 3Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 4New approach builds better proteins inside a computer 863 1New approach builds better proteins inside a computer 863 2New approach builds better proteins inside a computer 863 3New approach builds better proteins inside a computer 863 4Changing the global dietary environment 861 1Changing the global dietary environment 861 2Deadlines for 2007 National Soybean Rust Symposium fast approaching 859 1Deadlines for 2007 National Soybean Rust Symposium fast approaching 859 2Tolerance to inhalants may be caused by changes in gene expression 857 1Tolerance to inhalants may be caused by changes in gene expression 857 2
...7 - EPIX,Pharmaceuticals, Inc. (NASDAQ: EPIX) toda...X-00023, a novel long-acting 5-HT1A agonist,was f...l New,Clinical Drug Evaluation Unit (NCDEU) Meetin... by the National Institutes of,Health and the Amer...presentation highlighted data from a randomized,d...
... Prolexys,Pharmaceuticals and announced today a pu...ve small molecule anti-tumor agent,erastin. Prole...omics technology to understand the mechanism of ac...he June 14, 2007 issue,of the journal Nature revea...endent anion channels (VDACs) -- a novel target fo...
Other Medicine Technology:EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3,Clinical Trial at 47th Annual NCDEU Meeting 2EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3,Clinical Trial at 47th Annual NCDEU Meeting 3EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3,Clinical Trial at 47th Annual NCDEU Meeting 4Prolexys Pharmaceuticals and Columbia University Researchers,Publish Study on Anti-Tumor Properties of a Selective Small,Molecule Anti-Tumor Agent With Novel Mechanism of Action 2Prolexys Pharmaceuticals and Columbia University Researchers,Publish Study on Anti-Tumor Properties of a Selective Small,Molecule Anti-Tumor Agent With Novel Mechanism of Action 3
(Date:9/8/2008)...aser scalpels, arthroscopic,surgery, genomic resea...rinary medicine is quickly expanding into new high...e benefit; it,s improving medicine for,people, too... care for their pets to,treat diseases like diabet... according to the American Veterinary Medical Asso...
(Date:9/8/2008)...zine examines Iraq and Afghanistan veterans, strug..., Washington, DC (PRWEB) S...by veterans of the Iraq and Afghanistan wars about... addiction disorders are featured in the current i...ublication of the National Council for Community B...
(Date:9/7/2008)...f older patients successfully treated for colorect...le to detect any recurrence of cancer. The study, ... , a peer-reviewed journal of the American Cancer ...monitoring of colorectal cancer survivors could af...y curative surgery for colorectal cancer have an i...
(Date:9/7/2008)... appear to lower a man,s PSA level, the blood biom...her a man is at risk of prostate cancer. , But t.... 8 in the journal Cancer , caution that men shou... prostate cancer just yet. , "We showed that me...rin and other non-steroidal anti-inflammatory drug...
Breaking Medicine News(10 mins):Health News:High-Tech Vet Medicine Saving Lives of Pets and People 2Health News:Helping Veterans in Our Communities 2Health News:Helping Veterans in Our Communities 3Health News:Many colorectal cancer survivors do not receive recommended follow-up care 2Health News:Common painkillers lower levels of prostate cancer biomarker 2
...ly hurt in a farm accident, claimed a chance for s... The 16 year old teenage boy had suffered grave in... helicopter. Insp Roger McConnell, who accompanied...n't want to take all the credit, because the fire ...
...arize and improve collaboration regarding the emer...se, more specifically bird flu//, a training progr...scenario involving transfer of a suspected case of...er was simulated. The Baptist Hospital and the Qu...
...eat promise for new treatments for many conditions... types of adult tissue//. But the human embryo ste... scientists believe the human testicle may provide...or stem cell research. A German team has describ...
...g sensitive to noise, and do not like it much! Acc...noisy surroundings// may face an increased risk of... revealed that the chances of urban middle-aged ad...and amidst a lot of din, stood a 46 percent chance...
Other Medicine News:Health News:Human Testicular Cells Would Help In Stem Cell Research 2
...WideBiter Punch series facilitates fast and effect... smooth, anatomically shaped meniscal rim. The fla...e to access even the tightest joint spaces. Made i...f engineering experience in arthroscopy hand instr...
...WideBiter Punch series facilitates fast and effect... smooth, anatomically shaped meniscal rim. The fla...e to access even the tightest joint spaces. Made i...f engineering experience in arthroscopy hand instr...
...WideBiter Punch series facilitates fast and effect... smooth, anatomically shaped meniscal rim. The fla...e to access even the tightest joint spaces. Made i...f engineering experience in arthroscopy hand instr...
...WideBiter Punch series facilitates fast and effect... smooth, anatomically shaped meniscal rim. The fla...e to access even the tightest joint spaces. Made i...f engineering experience in arthroscopy hand instr...
Medicine Products: